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We have identified unique chemical and biological properties of a
cationic monofunctional platinum(II) complex, cis-diammine(pyr-
idine)chloroplatinum(II), cis-[Pt(NH3)2(py)Cl] or cDPCP, a coordi-
nation compound previously identified to have significant anti-
cancer activity in a mouse tumor model. This compound is an
excellent substrate for organic cation transporters 1 and 2, also
designated SLC22A1 and SLC22A2, respectively. These transporters
are abundantly expressed in human colorectal cancers, where they
mediate uptake of oxaliplatin, cis-[Pt(DACH)(oxalate)] (DACH 
trans-R,R-1,2-diaminocyclohexane), an FDA-approved first-line
therapy for colorectal cancer. Unlike oxaliplatin, however, cDPCP
binds DNA monofunctionally, as revealed by an x-ray crystal
structure of cis-{Pt(NH3)2(py)}2 bound to the N7 atom of a single
guanosine residue in a DNA dodecamer duplex. Although the
quaternary structure resembles that of B-form DNA, there is a
base-pair step to the 5 side of the Pt adduct with abnormally large
shift and slide values, features characteristic of cisplatin intrastrand
cross-links. cDPCP effectively blocks transcription from DNA tem-
plates carrying adducts of the complex, unlike DNA lesions of other
monofunctional platinum(II) compounds like {Pt(dien)}2. cDPCP–
DNA adducts are removed by the nucleotide excision repair appa-
ratus, albeit much less efficiently than bifunctional platinum–DNA
intrastrand cross-links. These exceptional characteristics indicate
that cDPCP and related complexes merit consideration as thera-
peutic options for treating colorectal and other cancers bearing
appropriate cation transporters.
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RNA polymerase II inhibition  x-ray crystal structure
The recent surge in clinical trials involving platinum antican-cer drugs reflects the efficacy and success rate of cisplatin,
the first and most potent member of the class (1). Most recently,
the FDA approved oxaliplatin as a first-line therapy for the
treatment of colorectal cancer (2). Since the advent of platinum-
based cancer therapy, several active compounds that violate the
classical structure–activity relationships for cisplatin have been
identified, including platinum(IV) (1) and polynuclear platinum
complexes (3), and platinum compounds with a trans stereo-
chemistry (4). In this report, we describe the results of structural
and mechanistic investigations of cis-diammine(pyridine)chlo-
roplatinum(II) (cDPCP, Fig. 1). The anticancer activity of this
cationic complex was established in murine tumor models almost
20 years ago (5, 6). However, perhaps because, unlike cisplatin,
cDPCP forms monofunctional rather than bifunctional lesions
with DNA, or because as a cation it was not expected to cross cell
membranes readily, the compound was never tested in humans.
Here, we describe experiments revealing (i) uptake of cDPCP
mediated by organic cation transporters (OCT) 1 and 2, (ii) the
x-ray crystal structure of a DNA dodecamer duplex containing
a monofunctional adduct of the complex bound to a central
guanosine residue, (iii) the ability of cDPCP–DNA adducts to
inhibit transcription, and (iv) reduced repair of cDPCP–DNA
adducts by the mammalian excinuclease relative to those of
cisplatin. The latter two cellular responses (iii and iv) are crucial
to the anticancer activity of cisplatin and oxaliplatin (7).
Cellular entry represents the first step in the mechanism of
action of platinum anticancer agents. Relative differences in
influx and efflux contribute to drug resistance and are a primary
factor in the differential response of various tumor types to the
drugs (8, 9). Copper transporters, including CTR1, facilitate
cellular uptake of cisplatin and oxaliplatin, but their importance
in mediating the anticancer activity of these compounds is
uncertain (10). Recently, we identified OCT1 and OCT2 as
critical mediators of oxaliplatin transport and toxicity in human
tissue. We detected mRNA from OCT1 in 20 of 20 tumor
samples from colon cancer patients and mRNA from OCT2 in
11 of 20 samples (11). There are three members of the human
OCT family: hOCT1 is expressed primarily in the liver; hOCT2
in the kidney; and hOCT3 in the liver, heart, brain, and placenta
(12). All are present in the intestinal/colorectal area to varying
degrees (11, 13). OCTs interact with organic substrates having
Mr 400 Da and overall positive charge (12). Oxaliplatin, a
neutral compound, is therefore transported only after loss of the
oxalate group to form mono- or dicationic species. Although
oxaliplatin and cisplatin form similar adducts on DNA, cisplatin
is a poor substrate for OCT1 and OCT2 compared with oxali-
platin (11) and is not active against colorectal cancer. These
properties suggest that OCT-mediated uptake of oxaliplatin into
cancer cells is a major determinant of its activity.
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Fig. 1. Chemical structures of cisplatin, oxaliplatin, and cDPCP.
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During the course of structure–function studies of Pt-based
OCT substrates, we identified the monofunctional cationic com-
plex cDPCP to have outstanding properties (see below). The
antitumor properties of cDPCP were initially established in a
sarcoma 180 ascites murine model study (5). The compound was
subsequently shown to block DNA replication at single dG sites
by replication mapping experiments, and a series of biochemical
experiments established that cDPCP forms a fundamentally
different adduct profile than the bifunctional cross-links of
cisplatin or oxaliplatin (6). Concern over the potential lability of
heterocyclic N-donor ligands, such as pyridine, in Pt(II) com-
plexes, has led to extensive investigations of the stability of their
DNA adducts. Although some complexes containing three N-
donor ligands, such as N-methyl-2,7-diazapyrenium, do form
bifunctional adducts after loss of the heterocycle (14), neither
pyridine nor ammonia dissociates from cDPCP upon DNA
binding (6, 14).
cDPCP is one of a few monofunctional platinum(II) com-
pounds that is active against tumor cells; most complexes in this
class, including [Pt(dien)Cl]Cl, dien  diethylenetriammine, and
the trans isomer of cDPCP, have limited to no cytotoxicity (5).
Exceptions include [PtIA2L]I complexes, where A2  2,9-
dimethyl-1,10-phenanthroline and L is an N-donor heterocyclic
ligand. The compound in which L  1-methylcytosine is more
toxic than cisplatin against a panel of 11 cell lines (15). Of
significance in the present context is the observation that the
greatest differential cytotoxicity occurred for the three colon
cancer lines among the 11 that were investigated.
Our primary objective in the present study was to understand
more fully the molecular mechanism of action of cDPCP. The
four early phases by which platinum compounds exert their
anticancer activity are cellular entry, activation (typically by
aquation), DNA binding, and the initial cellular responses to the
DNA damage (7). We were therefore interested to determine
whether cDPCP would improve upon the specificity of oxalipla-
tin for entry into cells expressing OCTs while sharing or exceed-
ing the potency of cisplatin. We examined cellular accumulation
of cDPCP vs. oxaliplatin because of organic cation transporters
and the effect of transporter expression on the sensitivity of
mammalian kidney cells to the compound. To determine the
influence of cDPCP on DNA geometry, we constructed a
site-specifically platinated dodecamer duplex containing a cen-
trally located cis-{Pt(NH3)2(py)}2–dG adduct and determined
its structure by x-ray crystallography. The consequences of
cDPCP binding to a plasmid DNA were also studied. To
investigate processing of cDPCP and cisplatin adducts by DNA
damage-recognition proteins, we used an in vitro system to study
repair of monofunctional platinum lesions by nucleotide excision
repair (hereafter ‘‘excision repair’’) and a cell-based -galacto-
sidase reporter assay to study the ability of the adducts to
inhibition transcription by RNA polymerase II. The results of
these experiments provide compelling evidence that cDPCP and
related compounds are excellent prospects for further preclinical
and clinical investigations as anticancer drugs.
Results
Cellular Accumulation and Pt-Induced Loss of Viability in OCT/
Cells. Mammalian cells stably transfected with a full-length
human OCT1 or OCT2 cDNA, or transfected with an empty
vector as a control, were used to study the cellular accumulation
and cytotoxicity of cDPCP and oxaliplatin. cDPCP is 87-fold
more cytotoxic in OCT1() than OCT1() cells, whereas
oxaliplatin was only 12-fold more effective. The cytotoxicity of
cDPCP in OCT2() cells increased by a factor of 137 over
OCT2() cells, compared with a 53-fold increase with oxalipla-
tin (Fig. 2). Examination of treated cells for platinum content
revealed that accumulation of cDPCP is 68-fold higher in
hOCT2-containing cells than in cells not expressing the trans-
porter. In hOCT1-containing cells, a 23-fold increase in platinum
accumulation was measured [supporting information (SI) Table
S1]. The corresponding numbers for oxaliplatin were 23-fold for
hOCT2 and 4.7-fold for hOCT1. Measurements of platinum
levels on DNA after cDPCP treatment were not obtained, but
DNA platination by oxaliplatin closely tracks its accumulation in
cells expressing hOCT1 and hOCT2 and can be reversed by
OCT1 and OCT2 inhibitors (11).
DNA-Binding Characteristics of cDPCP. X-ray structure. We synthe-
sized a DNA dodecamer duplex containing a site-specific cis-
{Pt(NH3)2(py)}2–dG adduct, crystallized the compound, and
collected x-ray diffraction data to 2.17-Å resolution (Table 1).
The structure was solved by using phases obtained from single-
wavelength anomalous diffraction data from the Pt atom. There
is one molecule in the asymmetric unit and a solvent content of
56%. The structure, depicted in Fig. 3, contains linear, B-form
DNA (Tables S2 and S3) with platinum coordinated to N7 of
guanine in the major groove. Watson–Crick hydrogen bonding
between the base pairs is maintained throughout the dodecamer
duplex. The double helix is unwound by 8° in the vicinity of the
platination site, a value in agreement with previous NMR
spectroscopic results of a heptamer duplex containing the
analogous cis-{Pt(NH3)2(4-Me-py)}2–dG adduct (16).
The pyridine ligand of the cis-{Pt(NH3)2(py)}2 moiety is
directed toward the 5 end of the platinated strand (Figs. 3 and
4). This orientation facilitates formation of a hydrogen bond
between the NH3 ligand trans to pyridine and O6 of the
guanosine residue (NO distance, 2.8 Å). Analysis of the
structure reveals that the platinated G-C base pair is displaced
toward the major groove to accommodate the platinum adduct.
The result is a base pair step to the 5 side of the platinum adduct
with abnormally large shift and slide values of 1.20 and 0.82 Å,
respectively (Fig. 3 and Table S2). Marzilli et al. (17) first
identified this structural feature as a common characteristic of
1,2-intrastrand cross-links formed by cisplatin.
Solution structural properties. We used supercoiled pBR322 DNA
and studied global platination with cDPCP in solution as a
function of bound platinum per nucleotide (rb), determined by
atomic absorption spectroscopy, to assess whether the adduct
unwinds the duplex in solution. This method is based on the
principle that negatively supercoiled circular DNA becomes
positively wound when the duplex is locally unwound, a phe-
nomenon encountered upon the formation of intrastrand cross-
Fig. 2. Cellular response to cDPCP and oxaliplatin. (Upper) Cell growth
inhibition assays for cDPCP (Left) and oxaliplatin (Right) in MDCK cells with
and without hOCT1. (Lower) IC50 values for both compounds in MDCK-OCT1
vs.-MOCK and HEK-OCT2 vs. -MOCK cells, expressed as mean  SD from three
experiments, with quadruplicate measurements obtained in each experiment.








links by cisplatin (18). Cisplatin unwinds the duplex by 13° per
bound platinum atom, visibly altering the electrophoretic mo-
bility of the supercoiled DNA on agarose gels. This result is
largely a consequence of the formation of intrastrand cross-links,
because monofunctional platinum complexes like [Pt(dien)Cl],
which can bind only to a single base, unwind duplex DNA by only
6° per Pt atom (19). We observe no unwinding of the superhelix
by cDPCP (Fig. S1) at rb values up to 0.034. This result is
consistent with the formation of monofunctional Pt–DNA ad-
ducts in solution. The amount of DNA-bound cDPCP per
amount added is, within experimental error, the same as that of
cisplatin, as revealed by plots of rb vs. rf, the formal ratio of
platinum added per nucleotide (Figs. S2 and S3).
Inhibition of Transcription by cDPCP in HeLa Cells. Among the
proteins and protein complexes that encounter cisplatin–DNA
adducts is the transcription apparatus. Unlike DNA poly-
merases, which briefly pause at, and then bypass, cisplatin
cross-links, presumably without major downstream effects (20),
RNA polymerases are greatly affected by the presence of these
adducts. The progression of human RNA polymerase II (Pol II)
along the DNA strand is almost completely blocked by cisplatin-
DNA adducts (21), and the arrest and subsequent ubiquitylation
of Pol II initiate transcription-coupled repair, a subpathway of
Table 1. Data collection and refinement statistics
Dataset SAD High resolution
Data collection statistics*
Beamline APS 24-ID-C† SSRL 9–2‡
Wavelength, Å 1.072 0.984
Space group C2221 C2221




Resolution range, Å 50–2.72 50–2.17
Obs. reflections 14,263 32,977
Unique reflections 2,264 4,765
Completeness 94.2 (73.6) 96.0 (76.0)
I/ 23.2 (6.7) 18.1 (2.7)










Average B-factors, Å2 42.4
Platinum ligand 44.4
Solvent 42.9
*Values in parentheses are for the highest-resolution shell.
†ADSC Q315 detector, 360 frames, 	  1°, exposure time  2 s.







Rfree  R obtained for a test set of reflections (5% of diffraction data).
Fig. 3. X-ray crystal structure of cDPCP-modified DNA. (A) Schematic diagram showing the DNA sequence and location of the platinum adduct for the complex
studied by x-ray crystallography. (B) Structure of the cDPCP-damaged DNA duplex, which maintains a linear B-form conformation despite binding of the Pt
complex. (C) Close-up view of the monofunctional Pt–dG adduct, with 2FoFc maps contoured at 1 (blue) and 15 (green), which show significant electron
density around the platinum atom. (D) The platinated base pair (blue) overlaid with ideal B-form DNA (gray). Platinum-binding forces the DNA bases out into
the major groove.
Fig. 4. Stereoscopic views of the cDPCP-dG adduct on duplex DNA. (Upper)
Watson-Crick hydrogen bonding. (Lower) 2FoFc electron density map con-
toured at 1.
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nucleotide excision repair, and programmed cell death, or
apoptosis (22).
Plasmids containing the lacZ gene downstream of an SV40
promoter were modified with cisplatin, cDPCP, or [Pt(dien)Cl] at
rb levels from 0 to 0.13 (Fig. S3) and transfected into HeLa cells. The
products of -galactosidase activity were assayed colorimetrically
after 24 h by addition of ortho-nitrophenyl--galactoside (ONPG).
Bypass of platinum adducts by the Pol II complex led to increased
transcription of the lacZ gene and absorbance at 420 nm arising
from ONPG cleavage by -galactosidase. There was a clear differ-
ence between Pol II bypass of cisplatin vs. [Pt(dien)Cl] adducts,
relative to that for the unplatinated control plasmids (Fig. 5 and Fig.
S4), with [Pt(dien)Cl] requiring 5 times the platination level as
cisplatin to block progression of RNA Pol II completely. In contrast,
transcription inhibition by the monofunctional cDPCP adducts very
nearly matched that of cisplatin and was much more effective than
inhibition by [Pt(dien)Cl]. Transcription of the cisplatin-modified
plasmid was effectively inhibited at an rb value of 2.5  103.
Inhibition by [Pt(dien)Cl]-modified plasmids was the same as that
of the unplatinated control at rb  7.8  103, whereas transcription
from the cDPCP-modified plasmid was reduced to 16% that of the
control at an rb value of 3.9  103 (Fig. 5).
Removal of Lesions by Excision Repair. The major product of
cisplatin-induced DNA damage, the intrastrand d(GpG) cross-
link (23, 24), is repaired by the excision repair pathway (25). The
integrity of this pathway in human cells is a key indicator of the
sensitivity of a tumor to platinum-based therapy. Human cells
from disorders in which excision repair deficiency is a phenotype,
such as xeroderma pigmentosum (26) and Cockayne syndrome
(27), are exquisitely sensitive to cisplatin damage. A test for the
presence of a key protein in the excision repair pathway, ERCC1,
is in FDA Phase III trials for use as a predictive factor in tailoring
chemotherapy to patients with nonsmall cell lung cancer (28).
Conversely, increased efficiency of excision repair leads to rapid
removal of cisplatin adducts and is associated with cisplatin
resistance in human tumor cells (29, 30).
We used 156-mer DNA probes (Figs. S5 and S6) site-
specifically platinated with adducts of cisplatin, cDPCP, or
[Pt(dien)Cl], and radioactively labeled with an internal 32P
modification, in combination with repair-active mammalian
cell-free extracts, to analyze excision repair. The samples were
resolved on denaturing polyacrylamide electrophoresis gels, and
the radioactive intensity was quantified with a phosphorimager.
Percentage repair was determined by comparing the intensity of
unrepaired 156-mer vs. that of the primary excision products at
25–29 bp. Repair efficiency of the three different site-specifically
platinated 156-mer probes in CHO nuclear extracts was quan-
titated as 3.5% for cisplatin-modified DNA, 1.0% for the cDPCP
adduct, and 0.3% for [Pt(dien)Cl]Cl adducted DNA after 60-min
reaction times (Fig. 5 and Fig. S7). The rate and amount of repair
are comparable to values observed for cisplatin and oxaliplatin
1,2-intrastrand d(GpG) cross-link-containing probes (25, 31–33)
and less than the 10% repair observed for cisplatin 1,3-
intrastrand d(GpTpG) cross-linked probes (33). Kinetic exper-
iments revealed that repair of the cDPCP adduct levels off after
60 min (Fig. 5 and Fig. S7), a result consistent with previous
measurements (25).
Discussion
cDPCP is an outstanding substrate for OCT1 and OCT2, as
revealed by the increased accumulation in cells that express these
critical transporters compared with those lacking them. The
dramatic enhancements in cellular accumulation and corre-
sponding cell sensitization indicate that cDPCP has a greater
tumor-targeting potential than oxaliplatin, the colorectal cancer
agent that owes its unique antitumor properties to specific
uptake by OCT1 and OCT2. Compared with oxaliplatin, cDPCP
is much less toxic to cells that do not express OCT1 or 2 (Fig. 1).
This property suggests that, like oxaliplatin, cDPCP will be able
to target colorectal or liver cancer but with a reduction in the
severity of side effects for tissues that do not express OCT1 or
OCT2. The presence of these transporters in certain organs,
most notably kidney and liver, may require the use of cotreat-
ments to mitigate toxic side effects. Nephrotoxicity, the dose-
limiting side effect for cisplatin therapy, is less problematic in
oxaliplatin treatment (34). Liver toxicity is a non-dose-limiting
side effect of cisplatin and oxaliplatin (35).
Compared with cisplatin, cDPCP causes only minor distor-
tions to double helical DNA upon binding to a guanine N7 atom
in the major groove. Characteristics of the cisplatin 1,2-
intrastrand d(GpG) cross-link include a roll angle of 26° between
the bound guanines and a 40° bend toward the major groove (36).
It is widely accepted that these structural distortions inhibit
Fig. 5. Repair and inhibition of transcription by cDPCP-DNA adducts. (A)
Comparison of repair of cDPCP with repair of cisplatin and [Pt(dien)Cl]Cl
adducts (gel, Inset), and comparison of the kinetics of repair of cisplatin and
cDPCP (bar plot). Gel lanes (Inset) are as follows: (1) ladder w/band at 25 nt, (2)
cisplatin 0 min, (3) cisplatin 30 min, (4) cisplatin 60 min, (5–7) cDPCP 0/30/60
min, (8–10) [Pt(dien)Cl]Cl 0/30/60 min. The entire gel is given in Fig. S7A. Error
bars represent the standard deviation of three separate experiments. (B)
Comparison of successful transcription bypass and repair of various Pt-DNA
adducts. Adducts of cDPCP, much like those of cisplatin, allow minimal bypass
by RNA polymerase II but are inefficiently repaired, similar to adducts of
[Pt(dien)Cl]Cl. Repair values report percentage excision products detected
after 60 min and transcription bypass values are given at rb  0.0039 for the
-gal live-cell assay. Repair error bars are the standard deviation of five, five,
and two separate experiments for cisplatin, cDPCP, and [Pt(dien)Cl]Cl, respec-
tively. Transcription error bars are the standard deviation of samples prepared
in triplicate. The entire experiment was performed twice.








transcription, leading either to nucleotide excision repair or to
apoptosis. A recent x-ray crystal structure of an RNA polymer-
ase II elongation complex containing a cisplatin 1,2-d(GpG)
intrastrand cross-link in the DNA template strand suggested that
the platinum adduct inhibits transcription by prohibiting trans-
location of the cross-link from the 2/3 site to the 2/1 site.
This barrier stems from the inability of the covalently linked
dinucleotide to twist by 90° for crossing the bridge helix in the
2/1 site (37). This finding provides a structural clue for
understanding transcription inhibition by cisplatin intrastrand
cross-links.
By contrast, monofunctional adducts of cDPCP offer no such
translocation barrier, because cDPCP binds covalently only to a
single DNA base. Modeling of the cis-{Pt(NH3)2(py)}2–dG ad-
duct into the template strand of the elongation complex suggests the
absence of a significant barrier to translocation between the 2 and
1 sites (data not shown). However, when the adduct is modeled
in the 1 site, where the incoming NTP is matched to the template
strand, of an elongation complex solved crystallographically (38), it
is clear that the pyridine ligand would sterically clash with the bridge
helix, in effect twisting the base out of its native conformation
(Fig. 6). This distortion could lead to NTP misincorporation,
which in turn might stall the polymerase. This hypothesis ex-
plains why cDPCP lesions inhibit transcription, whereas adducts
of the trans isomer and other monofunctional platinum com-
pounds like [Pt(dien)Cl]Cl, which would not cause such steric
hindrance, are much less potent inhibitors. Like cisplatin, tran-
scription is strongly inhibited by cDPCP both in cell extracts and
in live cells, but a significantly higher level of platination with
[Pt(dien)Cl] is required to block transcription to the same
extent.
Although cDPCP blocks transcription nearly as efficiently as
cisplatin, repair of cDPCP adducts by the mammalian excinucle-
ase is demonstrably reduced relative to repair of cisplatin or
oxaliplatin damage. Because cDPCP can largely escape repair
and yet inhibit transcription very effectively, its adducts should
persist longer than those of cisplatin yet produce a similar
number of downstream consequences that might raise the ther-
apeutic potential of cDPCP relative to cisplatin. The design of
anticancer agents specifically as transcription inhibitors has been
proposed, based on the premise that an extended delay in the
restoration of transcription would induce apoptosis by p53-
dependent and -independent pathways (39). If true, persistence
of transcription blocks would promote cell death and enhance
the potency of cDPCP. Combined with the high selectivity of
cDPCP for cells expressing hOCT1 and hOCT2, which are
broadly expressed in human colorectal cancer (11), these find-
ings support the candidacy of this unique monofunctional cat-
ionic complex as an anticancer drug.
Materials and Methods
Materials. Potassium tetrachloroplatinate(II) was obtained as a gift from
Engelhard Corporation (now BASF). Cisplatin (40) and cis-[Pt(NH3)2(py)Cl]Cl (5)
were synthesized as described. Phosphoramidites and other reagents for DNA
synthesis were purchased from Glen Research. Crystallization reagents were
obtained from Hampton Research and Sigma. Enzymes were purchased from
New England Biolabs. Plasmids pBR322 and pSV--galactosidase were pur-
chased from New England Biolabs and Promega, respectively, and were
amplified in 100 ml of LB cultures of E. coli XL1-blue cells containing ampicillin
as a selecting agent and purified on Maxi-prep columns (Qiagen). [-32P]ATP
was obtained from Perkin–Elmer. All other chemicals and solvents were
purchased from commercial suppliers.
Cellular Accumulation and Compound Cytotoxicity: Cell Lines and Transfection.
Madin–Darby canine kidney (MDCK) cells were stably transfected with full-
length human OCT1 cDNA (MDCK-hOCT1) and the empty vector (MDCK-
MOCK), as established (41). Human embryonic kidney (HEK293) cells stably
transfected with the full-length OCT2 cDNA (HEK-hOCT2) and with the empty
vector (HEK-MOCK) were also described (11).
Cell Culture. The stably transfected MDCK and HEK293 cells were cultured in
DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 g/ml strep-
tomycin (Invitrogen) and the respective selection antibiotics and grown at
37°C in a humidified atmosphere with 5% CO2.
Compound Cytotoxicity. Cytotoxicities of the compounds were determined by
plating cells in 96-well plates at a predetermined density. Cells were then
incubated overnight, and platinum complexes were added to the culture
medium. After 7 h, the medium was replaced with fresh Pt-free medium, and
the incubation was continued for a total of 72 h after the initial addition.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays
were performed as described (42).
Cellular Accumulation of Platinum. These studies were performed as described
(11).
X-Ray Crystal Structure Determination of Platinated DNA Duplex. Two deoxy-
oligonucleotides (5-CCTCTCGTCTCC-3 and its complementary strand) were
synthesized and purified by standard methods (43). The site-specifically pla-
tinated duplex was prepared and purified as described (44, 45). Details of
crystallization experiments, x-ray diffraction data collection, structure deter-
mination, and refinement are available in the SI Text.
DNA Unwinding Assays. Details of plasmid platination and agarose gel analysis
are available in the SI Text.
Transcription in Living Human Cells: Transcription Probe Preparation. The
pSV--galactosidase vector (Promega), containing a lacZ gene under the
control of an SV40 promoter and enhancer, was amplified in XL1-blue, puri-
fied on a Maxi-prep column (Qiagen) and globally platinated with either
cisplatin, cis-[Pt(NH3)2(py)Cl], or [Pt(dien)Cl] to yield rb values between 0 and
0.13. Excess platinum was removed by spin dialysis (Nanosep columns, Pall
Biosciences, 3K molecular weight cutoff), and DNA and Pt concentrations
were quantified by UV-vis and atomic absorption spectroscopy, respectively.
Transcription Assay. Experimental details are provided in SI Text.
Nucleotide Excision Repair Assay. Probes (156-mer) were prepared as described
in SI Text. Assays were performed as described (31, 46) with 10 fmol of the
platinated repair probe and 75 g of cell-free HeLa extract. Reactions were
allowed to proceed for 60 min at 30°C and were stopped by the addition of SDS
Fig. 6. Active site of RNA polymerase II, with a cDPCP–dG adduct (shown in
orange) modeled into template DNA (blue) at the 1 site, where incoming
NTPs are matched and added to synthesized RNA (red). Complementary
nontemplate DNA is shown in green. This model demonstrates how cDPCP
adducts may shift the template base out of its native conformation (shown in
dark blue) by steric interactions between the pyridine ligand and the Pol II
bridge helix, shown in gray. (Inset) Space-filling views of the Pt adduct and
bridge helix. Pol II coordinates: Protein Data Bank (PDB) ID code 2NVQ;
cDPCP-dG coordinates: this work.
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and proteinase K to final concentrations of 0.34% and 20 g/ml, respectively.
After extraction with 25:24:1 phenol:chloroform:isoamyl alcohol and careful
ethanol precipitation with 10 g of linear polyacrylamide as coprecipitant,
reaction products were analyzed by 10% urea-PAGE.
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